 |
|
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):1-15. Published online 2023 Jul 21 DOI: https://doi.org/10.3350/cmh.2023.0125
|
|
Citations to this article as recorded by
 Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
Hye Yeon Chon
The Korean Journal of Gastroenterology.2024; 83(2): 78. CrossRef An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness
Hao Peng, Kun Feng, Weilu Jia, Yunxin Li, Qingpeng Lv, Yewei Zhang
Apoptosis.2024;[Epub] CrossRef Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
Ji Eun Han, Hyo Jung Cho
Clinical and Molecular Hepatology.2024; 30(2): 160. CrossRef Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
Yonsei Medical Journal.2024;[Epub] CrossRef
|